MA-LOADSPRING-SOLUTIONS
14.9.2022 19:31:33 CEST | Business Wire | Press release
LoadSpring Solutions, Inc., the enterprise market leader in project platform solutions, has accepted a strategic majority interest investment from Blattner Technologies. Blattner Technologies is on a mission to be the leading provider of Predictive TransformationTM services and tools in the data analytics, artificial intelligence, and machine learning industries.
LoadSpring’s partnership with Blattner Technologies aligns with our industry focus on digital transformation and advancing data usability, analytics, machine learning, and artificial intelligence. Blattner’s focus on AI and predictive technologies will help lead to our customers' next generation of advancement.
“Today’s investment announcement will enable LoadSpring to rapidly expand its vision of driving the project controls industry to a future where it aspires to be. This new partnership, including the additional board membership, will accelerate our platform development and AI/analytics technology innovation to enable faster geographic and industry expansion, truly unlocking LoadSpring’s potential. Together, our expertise in providing global cloud solutions for project-based organizations and our new partner's expertise in building companies will provide next-generation solutions for our customers,” states Eric Leighton, President and CEO of LoadSpring Solutions, Inc.
Blattner Technologies’ CEO Russ Blattner says, “LoadSpring has the resources and tools to complement the list of companies Blattner Technologies is acquiring in our mission to build a predictive transformation model that takes our customers from the basics of data management and analytics to operationalizing AI/ML and true predictive analytics throughout an organization.”
LoadSpring’s global office locations and executive management teams will remain in place, with Eric Leighton continuing in his leadership role as President and CEO. Blattner Technologies representatives Russ Blattner and John Leschorn, along with Terrance Berland, co-founder of Unicorn & Lion, LLC, will join the LoadSpring Board of Directors, providing operational and technology vision to drive customer solutions into the future.
“This investment combines secure technology infrastructure and next-generation tools and analytics to create a truly distinctive solution offering for customers. This is an industry trend that will continue as organizations better understand the power of controlling and mining their data and look for partners that can bring them complete solutions, not just pieces,” says Terrance Berland, a member of the Forbes Technology Council.
About Blattner Technologies
Nashville, TN Blattner Technologies – Building on a 115-year legacy of innovation by the Blattner family of companies, Blattner Technologies is on a mission to be the leading provider of Predictive TransformationTM services and tools in the data analytics, artificial intelligence, and machine learning industries.
About LoadSpring
Founded in 1999, LoadSpring is a global project management provider obsessed with offering advanced managed cloud services. LoadSpring delivers expert project management and control solutions, fast data and business intelligence access, and hundreds of best-of-breed project-based applications. Data safety is assured through SOC 2 Type II security certification, providing an impenetrable cloud environment. LoadSpring customers and partners get higher productivity and ROI through our proprietary project platform while reducing the burden on their IT departments.
For more information, contact Stacey Witt at switt@loadspring.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006196/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom